Medical device company DexCom (NASDAQ: DXCM) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be around $5.21 billion, close to analysts’ estimates. Its non-GAAP profit of $0.68 per share was 4.5% above analysts’ consensus estimates.

Is now the time to buy DXCM? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management attributed the quarter’s performance to the broad rollout of the G7 15-day sensor system in the U.S., which generated positive initial feedback from both customers and physicians due to improved wear time and accuracy. Operational improvements in manufacturing and logistics, such as reestablishing more efficient ocean shipping routes and addressing prior sensor deployment issues, were also highlighted as contributors to margin improvements this quarter. CEO Jacob Steven Leach emphasized that sell-through trends improved as the quarter progressed, supported by efforts to build inventory and streamline the customer support experience through digital initiatives like My Dexcom Account.

Looking ahead, DexCom’s management expects continued growth driven by expanded access to continuous glucose monitoring (CGM) technology, especially as coverage for type two non-insulin users potentially broadens in the U.S. and internationally. The company plans to leverage new product features, such as Smart Basal for basal insulin users and enhanced digital support tools, to improve customer engagement and utilization. CFO Jereme Sylvain noted that gross margin expansion is anticipated to continue as manufacturing efficiencies and the contribution from the G7 15-day sensor increase. Management also expressed confidence in scaling their business internationally, with plans to introduce additional CGM products and pursue broader healthcare coverage, particularly as evidence supporting positive patient outcomes grows.

Key Insights from Management’s Remarks

Management attributed fourth quarter success to the U.S. launch of the G7 15-day sensor, operational improvements, and robust international performance, while ongoing investments in digital tools and product innovation set the foundation for future growth.

• G7 15-day sensor rollout: The U.S. launch of the G7 15-day system received strong feedback for its longer wear time and improved accuracy, reducing patient burden and supporting initial market adoption. Management is focused on increasing awareness and conversion from existing users to the new sensor platform.

• Operational efficiency gains: The company reported progress in manufacturing and logistics, including building inventory to preferred levels, optimizing shipping routes, and addressing previous sensor deployment issues. These efforts contributed to higher gross margins and fewer customer complaints related to sensor performance.

• International market growth: International revenues grew faster than U.S. revenues, with particular strength in France, Germany, and the United Kingdom. Expanded CGM access, especially for type two diabetes patients in France, was cited as a key driver.

• Digital support and AI integration: The launch of My Dexcom Account and upcoming AI-driven features are streamlining customer support and enhancing patient experience. Management sees these digital tools as critical to improving customer retention and lifetime value.

• Expanded product portfolio: Early access to Smart Basal for type two diabetes patients on basal insulin, a new patch technology for improved sensor adhesion, and updates to the Stelo app with comprehensive nutrition tracking reflect ongoing product development aimed at addressing a broader patient population.

Drivers of Future Performance

Management expects future performance to be shaped by expanded CGM access, manufacturing efficiencies, and new product introductions, with a focus on margin improvement and international expansion.

• Broader coverage and access: Management anticipates that expanded insurance coverage for type two non-insulin diabetes patients, particularly through potential Medicare decisions and international reimbursement, will significantly increase the addressable market for CGM devices. CEO Jacob Steven Leach emphasized the potential impact of unlocking coverage for up to 12 million additional U.S. patients.

• Manufacturing investments and margin expansion: The new Ireland manufacturing facility is expected to drive production efficiencies, although initial costs will be reflected in operating expenses before shifting to cost of goods sold. CFO Jereme Sylvain highlighted that gross margin improvement will come from lower freight costs, manufacturing scale, and increased adoption of the G7 15-day platform.

• Product innovation and digital enhancements: Management is prioritizing new product launches, such as Smart Basal and the next-generation Stelo app, alongside AI-driven support features. These are intended to drive higher utilization, retention, and engagement across DexCom’s growing global user base.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory analyst team will be watching (1) progress on Medicare and international coverage expansion for type two non-insulin patients, (2) adoption rates and user feedback for the G7 15-day sensor system, and (3) execution of the new Ireland manufacturing facility and its impact on margins. Additional milestones include updates on Smart Basal deployments and the launch of enhanced digital tools that may influence utilization and retention.

DexCom currently trades at $65.03, in line with $65.08 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.